Report by the Spanish Foundation of the Brain on the social impact of Alzheimer disease and other types of dementia. / Informe de la Fundación del Cerebro. Impacto social de la enfermedad de Alzheimer y otras demencias.

INTRODUCTION: Knowledge of the socioeconomic impact of dementia-related disorders is essential for appropriate management of healthcare resources and for raising social awareness. METHODS: We performed a literature review of the published evidence on the epidemiology, morbidity, mortality, associated disability and dependence, and economic impact of dementia and Alzheimer disease (AD) in Spain. CONCLUSIONS: Most population studies of patients older than 65 report prevalence rates ranging from 4% to 9%. Prevalence of dementia and AD is higher in women for nearly every age group. AD is the most common cause of dementia (50%-70% of all cases). Dementia is associated with increased morbidity, mortality, disability, and dependence, and results in a considerable decrease in quality of life and survival. Around 80% of all patients with dementia are cared for by their families, which cover a mean of 87% of the total economic cost, resulting in considerable economic and health burden on caregivers and loss of quality of life. The economic impact of dementia is huge and difficult to evaluate due to the combination of direct and indirect costs. More comprehensive programmes should be developed and resources dedicated to research, prevention, early diagnosis, multidimensional treatment, and multidisciplinary management of these patients in order to reduce the health, social, and economic burden of dementia.

[Neurocognitive screening in substance addicts: the Montreal Cognitive Assessment]. / Cribado neurocognitivo en adictos a sustancias: la evaluacion cognitiva de Montreal.

INTRODUCTION: The detection of neurocognitive disorders in addicts would allow subjects with functional impairment to be assigned to cognitive rehabilitation programmes. The Montreal Cognitive Assessment (MoCA) is a screening test that can be a valuable aid with this kind of patient. AIMS: To use the MoCA with a sample of subjects with addictions who are receiving treatment and to compare the results with the criteria proposed for the general population, mild cognitive impairment and early dementias. It also intends to examine the concurrent validity with global execution tests and the relationship with socio-demographic variables and others related to addiction. PATIENTS AND METHODS: The MoCA and the Allen Cognitive Level Screen-5 (ACLS-5) test were administered to a sample of 79 patients with addiction who were beginning treatment in a specific centre. RESULTS: Only 29.1% of the participants presented normal performance in terms of the criteria proposed by the authors. The others achieved scores below the cut-off point, many of them displaying an alarmingly low score, even when compared with criteria for mild cognitive impairment and early dementias. The MoCA showed concurrent validity with the ACLS-5 and correlation with academic level, but not with variables related to addiction. CONCLUSIONS: The MoCA is a test that is quick and simple to administer and correct. It allows the detection of subjects with extremely low cognitive performance that require neuropsychological and occupational interventions for cognitive rehabilitation, which increases treatment compliance and the benefits to be gained from other interventions with important cognitive demands, such as relapse prevention psychotherapy.

[Prevalence of attention-deficit hyperactivity disorder in substance addiction: from screening to diagnosis]. / Prevalencia del trastorno por deficit de atencion/hiperactividad en adictos a sustancias: del cribado al diagnostico.

INTRODUCTION: There is a rich body of literature on the coexistence of diagnostic criteria for attention deficit hyperactivity disorder (ADHD) and substance abuse/dependence. Prevalence, however, varies considerably from one work to another. AIMS: To apply an algorithm that takes into account all the criteria needed to reach an adequate diagnosis and to explore the conditions associated with false positives. PATIENTS AND METHODS: The diagnostic algorithm was applied using several tests in the different phases, i.e. the Attention Deficit Hyperactivity Disorder Self-Report Scale was used for screening, the Wender-Utah Rating Scale and the Parents' Rating Scale were administered for the retrospective diagnosis, and the self-administered Spanish version of the frontal behaviour scale and the perceived stress scale were used to study false positives. Symptoms of other axis I disorders were also explored and a battery of classic neuropsychological tests was administered. All this was carried out with a sample of 696 subjects whose treatment began in a care centre for drug addicts. RESULTS: The final prevalence was found to be 6.89%. The symptoms of the false positives in the screening test prior to consumption were similar to those of the true negatives, but in that moment those symptoms were similar to those of the true positives, with whom no differences were found in the neuropsychological performance. Generalised anxiety disorder was the one that showed the highest relation with false positives. CONCLUSIONS: The diagnostic category of ADHD is usually utilised indiscriminately to classify subjects with early-onset neurological disorders and those who present similar manifestations following the phase of active addiction to substances. There is a need for a neurological and neuropsychological study that goes beyond the mere symptoms so as to be able to carry out a suitable characterisation and treatment of a set of similar symptomatic manifestations, but with a very wide range of developmental and aetiopathogenic components.

[Cognitive remediation in addictions treatment]. / Rehabilitacion cognitiva en el tratamiento de las adicciones.

More recent theories of addiction suggest that neurocognitive mechanisms, such as attentional processing, cognitive control, and reward processing play a key role in the development or maintenance of addiction. Ultimately, the addiction (with or without substances) is based on the alteration of brain decision-making processes. The neurosciences, particularly those responsible for behavior modification, must take into account the neurobiological processes underlying the observable behavior. Treatments of addiction usually do not take into account these findings, which may be at the base of the low retention rates and high dropout rates of addicted patients. Considered as an alteration of brain functioning, addiction could be addressed successfully through cognitive rehabilitation treatments used in other clinical pathologies such as brain damage or schizophrenia. Although there are few studies, it is suggest that intervention to improve patients' cognitive functioning can improve the efficiency of well-established cognitive-behavioral therapies, such as relapse prevention. This paper reviews the available evidence on cognitive rehabilitation in treating addiction as well as in other pathologies, in order to formulate interventions that may be included in comprehensive rehabilitation programs for people with addictive disorders.

[Frontal symptoms in substance abusers under treatment using the Spanish version of the Frontal System Behaviour Scale]. / Sintomatología frontal en adictos a sustancias en tratamiento mediante la versión española de la escala de comportamiento frontal.

INTRODUCTION AND AIMS: There are different studies that suggest a relationship between frontal symptoms and substance addiction. The Frontal System Behavior Scale is a questionnaire used to consider the manifestations of three frontal syndromes: executive dysfunction, apathy and lack of inhibition. SUBJECTS AND METHODS: The Spanish version of the Frontal System Behavior Scale (FrSBe-Sp) is administered to 215 addicted individuals starting treatment and to 267 nonclinical participants. The FrSBe-Sp is a self-administered questionnaire of 46 items that evaluate the three syndromes afore- mentioned, in an estimation of baseline (before substance use) and in a present estimation (after substance consumption). RESULTS: The questionnaire shows suitable psychometric properties and convergent validity with another similar questionnaire (DEX-Sp). Statistically significant differences appear between the scores of the addicted individuals compared with the group control at the baseline, as well as, specially, the present time. CONCLUSIONS: The results point out the fact that possibly the alterations of frontal character were previous. Maybe they acted as some kind of risk factors at the beginning of substance use. Also, they have significantly increased during the phase of active substance use. The FrSBe-Sp seems to be a good instrument to explore, both synchronically and diachronically, symptoms of frontal type related to addictive behaviors. New hypotheses of special relevance for treatment of addictive behaviors are suggested.

[Dysexecutive symptoms in substance abusers under treatment using the Spanish version of the dysexecutive questionnaire (DEX-Sp)]. / Sintomatología disejecutiva en adictos a sustancias en tratamiento mediante la versión española del cuestionario disejecutivo (DEX-Sp).

INTRODUCTION AND AIMS: Dysexecutive syndrome has traditionally been related to alterations affecting the functioning of the frontal lobes of the brain. Different studies suggest that this syndrome is present in addicts to substances and, hence, the use of a brief questionnaire has been put forward as a way of carrying out an initial screening for the condition, prior to a thorough assessment of the executive functions by a neuropsychologist. SUBJECTS AND METHODS: The Spanish version of the dysexecutive questionnaire (DEX-Sp) was administered to 176 addicts who were beginning treatment and to 213 non-clinical (control) participants. The DEX is a 20-item self report that evaluates a wide range of dysexecutive symptoms. RESULTS: Statistically significant differences appeared between the scores of addicts and those obtained by the control group. Whereas males showed differences in the types of symptoms they reported, female addicts displayed more intense dysexecutive clinical features, which affected all the areas under frontal control. No significant differences were observed as regards the main drug of abuse. CONCLUSIONS: It can be established that a total score of 24 points or more on the complete DEX-Sp scale suggests the existence of dysexecutive symptoms that are clinically relevant. Likewise, scores of 33 points or more indicate a probable moderate or severe dysexecutive syndrome. The DEX seems to be an instrument that is sensitive, fast and easy to apply in the initial assessment of addicts who are seeking treatment.